TELA - NASDAQ
TELA Bio, Inc.
$1.14
+0.44%TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
At a Glance
Live SnapshotTELA Bio, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
TELA Bio, Inc. Cash Flow Statement
TELA • NASDAQ
| TELA Bio, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-38.8M | -37.8M | -46.7M | -44.3M | -33.3M | -28.8M | -22.4M | -21.1M | -21.3M | |
1M | 1M | 808K | 1.2M | 535K | 525K | 582K | 1.2M | 761K | |
230K | -144K | 0.0 | 0.0 | 14K | 0.0 | 5K | 1.2M | -40K | |
3.8M | 4.4M | 5M | 4M | 3.7M | 2.1M | 457K | 216K | 197K | |
4.1M | -4.1M | 1.6M | 4.1M | 2.1M | 1.8M | 2.1M | 2.9M | 4M | |
1.5M | -4.9M | -1.7M | -5.8M | -3.5M | -86K | -6.2M | -4.5M | 75K | |
-28.2M | -41.6M | -40.9M | -40.7M | -30.4M | -24.5M | -25.5M | -19.9M | -16.4M | |
INVESTING ACTIVITIES | |||||||||
-448K | (0.0) | -611K | -872K | -627K | -167K | -2.7M | -1.6M | -114K | |
(1.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (4K) | (13K) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -9.3M | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.3M | 0.0 | 0.0 | 0.0 | |
0.0 | 4.5M | 12K | -1M | 0.0 | 0.0 | 0.0 | 4K | 13K | |
(846K) | (4.5M) | -599K | -1.9M | -627K | (9.1M) | -12M | -1.6M | -101K | |
FINANCING ACTIVITIES | |||||||||
11.9M | 42.9M | 46.3M | 34.4M | 585K | 44.7M | 51.2M | 0.0 | 0.0 | |
14M | 0.0 | 0.0 | 10M | 0.0 | 0.0 | 0.0 | 25M | 12.2M | |
(105K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-205K | 138K | -74K | -3.5M | 0.0 | -313K | 14K | -1.6M | 14.1M | |
25.8M | 43.1M | 46.3M | 40.9M | 585K | 44.4M | 65.5M | 27.4M | 26.3M | |
CASH FLOW SUMMARY | |||||||||
-217K | 28K | 164K | -144K | 11K | 17K | -4K | 0.0 | 0.0 | |
-1.8M | 5.9M | 5M | -1.9M | -30.5M | 29.1M | 28M | 5.9M | 9.9M | |
52.9M | 47M | 42M | 43.9M | 74.4M | 45.3M | 17.3M | 11.3M | 1.5M | |
51.1M | 52.9M | 47M | 42M | 43.9M | 74.4M | 45.3M | 17.3M | 11.3M | |
-28.7M | -42.6M | -41.5M | -42.6M | -31.1M | -24.6M | -28.2M | -21.5M | -16.5M |
SEC Filings
TELA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 30, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 17, 2026 | 2026 | |
S-3 S-3 N/A | December 12, 2025 | December 12, 2025 | ||
8-K 8-K 2025 N/A | November 14, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | October 31, 2025 | 2025 |
Related Guides
Continue your TELA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.